Burden of cerebral adrenoleukodystrophy on affected children and their families through the eyes of family caregivers

Abstract

Aim: This research assessed the needs of family caregivers of children with cerebral adrenoleukodystrophy (cALD), focusing on the diagnostic process; the burden of the disease on the child and their caregiver’s quality of life; and the physical, social, psychological, professional, and financial impacts on the whole family.

Methods: Family caregivers of children with cALD were recruited via the European Leukodystrophies Association International’s online platform, Leuconnect, to respond to a quantitative survey and a quality-of-life questionnaire and participate in a qualitative semi-structured interview. The questions focused on disease experience from onset to diagnosis and consequences on current life. Twelve family caregivers of 14 children were interviewed.

Results: cALD diagnosis took an average of 16.5 months, and 8 of 12 children were misdiagnosed, with parents often describing a lack of listening from doctors. Caregivers described bedridden children whose poor quality of life correlated with a high Neurologic Function Score. On average, they needed to care for their children 7.7 h/day, with serious consequences for their employment, social life, and psychological state.

Conclusion: Our interviews with family caregivers helped us to consider limiting diagnostic wandering by improving the skills of general practitioners and public knowledge of pathology. By gathering information on precise daily routines centered around a dependent child, we can better understand how to effectively support families by adapting not only the global care of the child but also to the following needs expressed for the entire family: better information, coordination of both care and administrative procedures, and real respite.

Keywords

Cerebral adrenoleukodystrophy / cALD / initial symptoms / diagnostic delay / burden / caregiver experience / quality of life

References

[1] Engelen M,de Visser M.X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management.Orphanet J Rare Dis2012;7:51 PMCID:PMC3503704

[2] Stone RT.Natural history of brain lesions in X-linked adrenoleukodystrophy: on-again, off-again.Neurology2020;94:1058-9

[3] Bezman L,Raymond GV.Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening.Ann Neurol2001;49:512-7

[4] Aubourg P.X-linked adrenoleukodystrophy.Ann Endocrinol (Paris)2007;68:403-11

[5] Cappa M,Vollono C,Banni S.Adrenoleukodystrophy.Endocr Dev2011;20:149-60

[6] Mahmood A,Dubey P,Moser HW.Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study.Lancet Neurol2007;6:687-92

[7] Raymond GV,Paker A.Survival and functional outcomes in boys with cerebral adrenoleukodystrophy with and without hematopoietic stem cell transplantation.Biol Blood Marrow Transplant2019;25:538-48

[8] Mallack EJ,Yan H.MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: meta-analysis and consensus guidelines.J Inherit Metab Dis2021;44:728-39 PMCID:PMC8113077

[9] Moser HW,Raymond GV.X-linked adrenoleukodystrophy.Nat Clin Pract Neurol2007;3:140-51

[10] Loes DJ,Moser H.Adrenoleukodystrophy: a scoring method for brain MR observations.AJNR Am J Neuroradiol1994;15:1761-6 PMCID:PMC8333737

[11] Moser HW,Lu SE.Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil.Arch Neurol2005;62:1073-80

[12] Miller W.Stem cell-transplantation therapy for adrenoleukodystrophy: current perspectives.J Neurorestoratology2017;5:5-19

[13] Bessey A,Leaviss J.Economic impact of screening for X-linked adrenoleukodystrophy within a newborn blood spot screening programme.Orphanet J Rare Dis2018;13:179 PMCID:PMC6182830

[14] Beckmann NB,Dietrich MS.Quality of life among boys with adrenoleukodystrophy following hematopoietic stem cell transplant.Child Neuropsychol2018;24:986-98

[15] van den Broek BTA,Paviglianiti A.Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies.Blood Adv2018;2:49-60 PMCID:PMC5761624

[16] Lee TY,Liaw JJ.The lived experience of Taiwanese mothers of a child diagnosed with adrenoleukodystrophy.J Health Psychol2014;19:195-206

[17] Kuratsubo I,Shimozawa N.Parents of childhood X-linked adrenoleukodystrophy: high risk for depression and neurosis.Brain Dev2008;30:477-82

[18] Chevalier J.Valuing EQ-5D using time trade-off in France.Eur J Health Econ2013;14:57-66

[19] RAND Corporation. 36-item short form survey from the RAND medical outcomes study. Available from: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form.html [Last accessed 3 Jan 2020]

[20] van Geel B,Haverkort E.Delay in diagnosis of X-linked adrenoleukodystrophy.Clin Neurol Neurosurg1993;95:115-20

[21] Haren K, Bonkowsky JL, Bernard G, et al; GLIA Consortium. Consensus statement on preventive and symptomatic care of leukodystrophy patients.Mol Genet Metab2015;114:516-26

[22] Namkung EH,Greenberg JS,Floyd FJ.The relative risk of divorce in parents of children with developmental disabilities: impacts of lifelong parenting.Am J Intellect Dev Disabil2015;120:514-26 PMCID:PMC4624231

[23] Tay J,Stremler R.Self-reported experiences of siblings of children with life-threatening conditions: a scoping review.J Child Health Care2022;26:517-30 PMCID:PMC9667075

[24] Migliorini L.Challenging gender perspective in the community to promote well-being and health.J Prev Interv Community2020;48:121-31

[25] Maladies Diseases Info Services. L’Observatoire resultats et analyses Le parcours de santé et de vie. Available from https://www.maladiesraresinfo.org/s%E2%80%99informer-sur-les-maladies-rares/observatoire-des-maladies-rares.html [Last accessed 3 Jan 2020]

[26] Cardinali P,Rania N.The caregiving experiences of fathers and mothers of children with rare diseases in Italy: challenges and social support perceptions.Front Psychol2019;5:10 PMCID:PMC6690318